ECS Botanics Holdings Ltd (ASX:ECS) disclosed full-year FY26 revenue of $21.4 million, representing a 10% year-on-year increase, alongside a positive EBITDA of $0.6 million, at its 2026 Annual General Meeting presentation dated 18 November 2026.
Key Points
- FY26 revenue reached $21.4 million, up 10% year-on-year, with EBITDA of $0.6 million, an improvement of $5.8 million year-on-year
- FY26 operating cash flow was positive $0.5 million, a $5.6 million improvement year-on-year from negative $5.1 million in FY25
- PCE cannabis production reached 5.3 tonnes in FY26, up 43% year-on-year, while outdoor trimmed flower production was 3.1 tonnes, up 12% year-on-year
- Q1 FY27 quarterly sales totalled $5.49 million, up 13.1% quarter-on-quarter, with branded B2C sales of $3.91 million representing approximately 71% of sales
- October branded B2C sales reached $1.50 million, described as a record month, up 9.1% month-on-month and 16.3% year-on-year
FY26 Financial and Production Performance
According to the AGM presentation, ECS Botanics reported FY26 branded B2C Q4 sales of $3.45 million, up 31% year-on-year, representing approximately 71% of Q4 revenue. Production cost per gram was reduced, with PCE costs down 33% and outdoor costs down 44%. The company disclosed that its operational cultivation infrastructure comprises 26 protective cropping enclosures, and stated that major infrastructure investment is largely complete, with focus now on utilisation, yield, cost per gram and returns. The filing noted five consecutive quarters of positive operating cash flow, with Q1 FY27 operating cash flow of positive $243,000.
Branded Portfolio and International Expansion
The filing disclosed that OzSun flower sales in Q1 FY27 reached $1.33 million, up 44.5% year-on-year, while AVANI capsule sales grew 35.7% year-on-year, with 52.6% of AVANI capsule sales derived from VESIsorb products. Australian branded product sales for the July to October FY27 period totalled $5.42 million, up 21.7% year-on-year. The OzSun brand launched in Germany in June 2026, with the filing stating the initial shipment sold within two weeks. The company disclosed plans to launch six OzSun-branded Australian-grown flower products in the United Kingdom through Curaleaf, with initial supply targeted for late 2026, subject to regulatory requirements.
Commercial Priorities Disclosed at Annual General Meeting
The AGM presentation, delivered by Chairman Jeremy King and CEO and Managing Director Nan-Maree Schoerie, outlined the company's stated commercial focus areas as growing Australian brands, converting international pathways across Germany, the United Kingdom, Poland and New Zealand, leveraging intellectual property, and improving returns from the existing platform. The filing stated that Poland's first flower registration has been approved. The presentation noted that ECS's market momentum grew 11.9% quarter-on-quarter, compared with a broader tracked panel decline of 1.9%, based on a Nostradata pharmacy panel subset described as indicative only.



Please wait processing your request...